Head and Neck Cancer Clinical Trial
Official title:
Restoration of Radioiodine Uptake in Thyroid Carcinoma: A Clinical Trial
RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine.
This would allow the cancer to be detected and treated by radioactive iodine.
PURPOSE: Phase I trial to study the effectiveness of azacitidine to restore thyroid function
in treating patients who have persistent or metastatic thyroid cancer.
OBJECTIVES: I. Determine the ability of azacitidine to restore iodine uptake by
dedifferentiated thyroid cancer, enabling detection and treatment with iodine I 131 in
patients with metastatic follicular or papillary thyroid cancer. II. Evaluate different
doses and schedules of azacitidine administration to determine an optimally effective
combination for restoration of iodine I 131 uptake with acceptable toxicity in this patient
population. III. Determine the efficacy of azacitidine plus iodine I 131 in this patient
population.
OUTLINE: This is a dose escalation study of azacitidine. Patients undergo a control phase
consisting of oral liothyronine sodium twice daily on weeks 1-4 and a low iodine diet on
weeks 4-7. At week 6, patients receive a scan dose of iodine I 131 followed by whole body
scanning over 5 days. Beginning at week 7, patients undergo a treatment phase consisting of
oral liothyronine sodium twice daily for 3 weeks, azacitidine subcutaneously daily for 10 or
20 days (weeks 7-11) and a low iodine diet on weeks 8-11. During week 11, patients undergo
additional whole body scanning over 5 days followed by a therapeutic dose of iodine I 131.
Patients achieving successful therapy receive 5 additional doses of azacitidine. Cohorts of
4 patients receive escalating doses of azacitidine until demonstrable radioiodine uptake is
seen or the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose
preceding that at which 2 of 8 patients experience dose limiting toxicity. Patients are
followed weekly for 8 weeks.
PROJECTED ACCRUAL: A total of 38 patients will be accrued for this study.
;
Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
| Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
| Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
| Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
| Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
| Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
| Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
| Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
| Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
| Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |